The Centre for Innovation in Regulatory Science (CIRS) is guided by the objectives of its predecessor organisation, the CMR International Institute for Regulatory Science (the Institute), embracing and continuing to fulfil and expand the Institute’s mission and objectives. CIRS is the vehicle through which the international pharmaceutical industry, regulatory authorities and academia meet, debate and develop regulatory policy. The objectives of CIRS are to facilitate dialogue and productive discussions in order to promote better understanding of the science that will form the basis for regulatory policy; to play an active and pro-active role in the evolution and harmonisation of international regulatory requirements and approval procedures to act as a catalyst for the adoption of best practice in global regulatory affairs; to provide a neutral, professional forum through which peers can meet and share best practice; and to pursue research that supports the CIRS mission.
Mission: To maintain a leadership role in identifying and applying scientific principles for the purpose of advancing regulatory and HTA policies and processes in developing and facilitating access to medicinal products.
History of CIRS:
The CMR International Institute for Regulatory Science was established in 2002 under the auspices of CMR International Ltd. to assume the important role of providing a neutral forum in which senior executives from pharmaceutical companies, government regulatory agencies and academia could discuss current issues in an open-minded, intimate, and interactive environment.
In 2010, the Institute was reorganised as the Centre for Innovation in Regulatory Science Ltd., to reflect its maturing mission and to best address the objectives of the organisation. Further, this evolutionary change allows CIRS to more clearly distinguish its role and activities from those of CMR International Ltd. CIRS continues the original mission of the Institute while also addressing the related issue of the role of health technology assessment in the processes of developing medicines and expediting patients’ access to these therapies.
CIRS – The Centre for Innovation in Regulatory Science – is a neutral, independent UK-based subsidiary company, forming part of Clarivate Analytics, formerly the IP&Science business of Thomson Reuters. It is governed pursuant to constitutional documents that assure it is operated for the sole support of its members’ activities. CIRS has its own dedicated management and advisory boards, and its funding is derived from membership dues, related activities and grants.
